Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 703-709

  Fitzmaurice, Paul S ^a   Tong, Junchao ^b   Yazdanpanah, Mehrdad ^c   Liu, Peter P ^c   Kalasinsky, Kathryn S ^d   Kish, Stephen J ^b  

^a MT ALBERT RESEARCH CENTRE   (New Zealand)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; DOPAMINE; GLUTATHIONE; MALONALDEHYDE; METHAMPHETAMINE; URIC ACID;

ADULT; ARTICLE; AUTOPSY; BRAIN DAMAGE; BRAIN LEVEL; CAUDATE NUCLEUS; CEREBELLUM CORTEX; CONTROLLED STUDY; DRUG ABUSE; DRUG BRAIN LEVEL; DRUG INTOXICATION; DRUG USE; FEMALE; FRONTAL CORTEX; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ALDEHYDES; AMPHETAMINE-RELATED DISORDERS; BRAIN; BRAIN CHEMISTRY; DOPAMINE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MALONDIALDEHYDE; METHAMPHETAMINE; URIC ACID;

EID: 33751189188     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.109173     Document Type: Article

References (40)

1. Acikgoz O, Gonenc S, Kayatekin BM, Pekcetin C, Uysal N, Dayi A, Semin I, and Gure A (2000) The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex. Eur Neuropsychopharmacol 10:415-418.
2. Acikgoz O, Gonenc S, Kayatekin BM, Uysal N, Pekcetin C, Semin I, and Gure A (1998) Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res 813:200-202.
3. Chang L, Cloak C, Patterson K, Grob C, Miller EN, and Ernst T (2005) Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 57:967-974.
4. Davidson C, Gow AJ, Lee TH, and Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36:1-22.
5. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
6. Esterbauer H, Schaur RJ, and Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
7. Esterbauer H and Zollner H (1989) Methods for determination of aldehydic lipid peroxidation products. Free Radic Biol Med 7:197-203.
8. Flora G, Lee YW, Nath A, Maragos W, Hennig B, and Toborek M (2002) Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromol Med 2:71-85.
9. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, and Sonsalla PK (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152-160.
10. Hayn M, Kremser K, Singewald N, Cairns N, Nemethova M, Lubec B, and Lubec G (1996) Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Life Sci 59:537-544.
11. Iwashita A, Mihara K, Yamazaki S, Matsuura S, Ishida J, Yamamoto H, Hattori K, Matsuoka N, and Mutoh S (2004) A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J Pharmacol Exp Ther 310:1114-1124.
12. Jayanthi S, Ladenheim B, and Cadet JL (1998) Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann N Y Acad Sci 844:92-102.
13. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, et al. (2006) Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 185:327-338.
14. Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony RM, Furukawa Y, Guttman M, and Kish SJ (2001) Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int 116:163-169.
15. Kim HC, Jhoo WK, Choi DY, Im DH, Shin EJ, Suh JH, Floyd RA, and Bing G (1999) Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res 851:76-86.
16. Kita T, Shimada K, Mastunari Y, Wagner GC, Kubo K, and Nakashima T (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39:399-406.
17. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, et al. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
18. Luo XP, Yazdanpanah M, Bhooi N, and Lehotay DC (1995) Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry. Anal Biochem 228:294-298.
19. Lyras L, Cairns NJ, Jenner A, Jenner P, and Halliwell B (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 68:2061-2069.
20. Markesbery WR and Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36.
21. McCann UD and Ricaurte GA (2004) Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27:821-826.
22. Melchitzky DS and Lewis DA (2000) Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum: evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology 22:466-472.
23. Mirecki A, Fitzmaurice P, Ang L, Kalasinsky KS, Peretti FJ, Aiken SS, Wickham DJ, Sherwin A, Nobrega JN, Forman HJ, et al. (2004) Brain antioxidant systems in human methamphetamine users. J Neurochem 89:1396-1408.
24. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ, and Kish SJ (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 127:363-370.
25. O'Callaghan JP and Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
26. Odetti P, Garibaldi S, Norese R, Angelini G, Marinelli L, Valentini S, Menini S, Traverso N, Zaccheo D, Siedlak S, et al. (2000) Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 59:393-397.
27. Olsson H, Halldin C, Swahn CG, and Farde L (1999) Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 19:1164-1173.
28. Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, and McCann UD (2005) Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther 315:91-98.
29. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, and Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328.
30. Schuessel K, Leutner S, Cairns NJ, Muller WE, and Eckert A (2004) Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J Neural Transm 111:1167-1182.
31. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, and Bymaster FP (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50:755-760.
32. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, and London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028-6036.
33. Tong J, Ross BM, Schmunk GA, Peretti FJ, Kalasinsky KS, Furukawa Y, Ang LC, Aiken SS, Wickham DJ, and Kish SJ (2003) Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry 60:896-903.
34. Wan FJ, Lin HC, Huang KL, Tseng CJ, and Wong CS (2000) Systemic administration of D-amphetamine induces long-lasting oxidative stress in the rat striatum. Life Sci 66:PL205-PL212.
35. Williams TI, Lovell MA, and Lynn BC (2005a) Analysis of derivatized biogenic aldehydes by LC tandem mass spectrometry. Anal Chem 77:3383-3389.
36. Williams TI, Lynn BC, Markesbery WR, and Lovell MA (2005b) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 27:1094-1099.
37. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, and Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
38. Yamamoto BK and Zhu W (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287:107-114.
39. Yoshida K, Kaneko K, Miyajima H, Tokuda T, Nakamura A, Kato M, and Ikeda S (2000) Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 175:91-95.
40. Yuan J, Callahan BT, McCann UD, and Ricaurte GA (2001) Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem 77:1338-1347.